Pub Date : 2025-02-13DOI: 10.1001/jamaophthalmol.2025.0003
Sally S Ong
{"title":"Expanding Vision Services at Federally Qualified Health Centers.","authors":"Sally S Ong","doi":"10.1001/jamaophthalmol.2025.0003","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.0003","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1001/jamaophthalmol.2024.6064
Michael D. Yu, Michael Heiferman, Edward Korot, Aneesha Ahluwalia, Gina Yu, Prithvi Mruthyunjaya
ImportanceTumor thickness is a well-established risk factor for malignant transformation of choroidal nevus into melanoma. To date, reliable evaluation of tumor thickness relies on B-scan ultrasonography, which is frequently unavailable at nonsubspecialty clinics where most melanocytic choroidal lesions (MCLs) are first diagnosed.ObjectiveTo describe a technique for potential rapid and reliable estimation of MCL thickness using only Optomap ultra-widefield (UWF) images without B-scan ultrasonography.Design, Setting, and ParticipantsThis retrospective, exploratory, cross-sectional analysis of consecutive MCLs diagnosed at Byers Eye Institute, Stanford University, Palo Alto, California, investigates the quantitative correlation between B-scan ultrasonographic thickness of MCLs with the relative pixel intensity of MCLs on green-channel (GC) Optomap UWF images. Pixel intensity overlying the lesion was standardized to the pixel intensity surrounding the lesion (pixel intensity difference [PID]), which was then correlated with ultrasonographic tumor thickness in all study lesions using linear regression analysis. Data were collected from January 1, 2019, to July 1, 2021.Main Outcomes and MeasuresThe correlation between ultrasonographic tumor thickness and PID was measured. Performance (sensitivity and specificity) of the regression analysis trendline in estimating tumor thickness was also determined.ResultsA total of 138 MCLs from 138 patients (mean age, 57.0 years; 51% female) were included, comprising 125 that were nevi and 13 that were melanoma. The mean ultrasonographic tumor thickness was 1.1 mm (median, 0.8 mm; range, 0.2-5.5 mm), with a mean PID of 2.13. Stratifying lesions by ultrasonographic thickness (<1.0 mm vs 1.0-2.0 mm vs >2.0 mm), the mean PID increased (−1.95 vs 3.72 vs 17.62; P < .001) as mean thickness increased (0.5 mm vs 1.4 mm vs 3.3 mm; P < .001). PID was correlated with tumor thickness (R2 = 0.823; 95% CI, 0.770-0.875; P < .001) across lesions of all sizes.Conclusions and RelevanceIn this proof-of-principle study, GC-derived lesion intensity correlated well with ultrasonographic tumor thickness. Leveraging this correlation, this study demonstrates a technique for potentially reliable and rapid estimation of tumor thickness using UWF Optomap images without the use of B-scan ultrasonography.
{"title":"Pixel Intensity to Estimate Choroidal Tumor Thickness Using 2-Dimensional Ultra-Widefield Images","authors":"Michael D. Yu, Michael Heiferman, Edward Korot, Aneesha Ahluwalia, Gina Yu, Prithvi Mruthyunjaya","doi":"10.1001/jamaophthalmol.2024.6064","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.6064","url":null,"abstract":"ImportanceTumor thickness is a well-established risk factor for malignant transformation of choroidal nevus into melanoma. To date, reliable evaluation of tumor thickness relies on B-scan ultrasonography, which is frequently unavailable at nonsubspecialty clinics where most melanocytic choroidal lesions (MCLs) are first diagnosed.ObjectiveTo describe a technique for potential rapid and reliable estimation of MCL thickness using only Optomap ultra-widefield (UWF) images without B-scan ultrasonography.Design, Setting, and ParticipantsThis retrospective, exploratory, cross-sectional analysis of consecutive MCLs diagnosed at Byers Eye Institute, Stanford University, Palo Alto, California, investigates the quantitative correlation between B-scan ultrasonographic thickness of MCLs with the relative pixel intensity of MCLs on green-channel (GC) Optomap UWF images. Pixel intensity overlying the lesion was standardized to the pixel intensity surrounding the lesion (pixel intensity difference [PID]), which was then correlated with ultrasonographic tumor thickness in all study lesions using linear regression analysis. Data were collected from January 1, 2019, to July 1, 2021.Main Outcomes and MeasuresThe correlation between ultrasonographic tumor thickness and PID was measured. Performance (sensitivity and specificity) of the regression analysis trendline in estimating tumor thickness was also determined.ResultsA total of 138 MCLs from 138 patients (mean age, 57.0 years; 51% female) were included, comprising 125 that were nevi and 13 that were melanoma. The mean ultrasonographic tumor thickness was 1.1 mm (median, 0.8 mm; range, 0.2-5.5 mm), with a mean PID of 2.13. Stratifying lesions by ultrasonographic thickness (&amp;lt;1.0 mm vs 1.0-2.0 mm vs &amp;gt;2.0 mm), the mean PID increased (−1.95 vs 3.72 vs 17.62; <jats:italic>P</jats:italic> &amp;lt; .001) as mean thickness increased (0.5 mm vs 1.4 mm vs 3.3 mm; <jats:italic>P</jats:italic> &amp;lt; .001). PID was correlated with tumor thickness (<jats:italic>R</jats:italic><jats:sup>2</jats:sup> = 0.823; 95% CI, 0.770-0.875; <jats:italic>P</jats:italic> &amp;lt; .001) across lesions of all sizes.Conclusions and RelevanceIn this proof-of-principle study, GC-derived lesion intensity correlated well with ultrasonographic tumor thickness. Leveraging this correlation, this study demonstrates a technique for potentially reliable and rapid estimation of tumor thickness using UWF Optomap images without the use of B-scan ultrasonography.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"9 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1001/jamaophthalmol.2024.6065
Raziyeh Mahmoudzadeh, Mariam Samuel, Sydney Wheeler, Mirataollah Salabati, Christopher T. Leffler, Jessica D. Randolph
ImportanceThe COVID-19 pandemic has altered health care delivery, including ophthalmic care. Understanding how the pandemic has changed the rates of commonly performed ophthalmic procedures is crucial for assessing the broader implications for patient care and resource allocation.ObjectiveTo estimate the changes in the rates of the 10 most prevalent ophthalmic procedures among Medicare beneficiaries during the COVID-19 pandemic and to explore the geographic disparities in these shifts.DesignThis retrospective US cross-sectional study compared data from Medicare Part B National Summary Data Files for the calendar years 2019 and 2020. Participants included Medicare beneficiaries undergoing the 10 most common ophthalmic procedures. Data included a total of 3 879 533 procedure entries in 2019 and 3 181 439 entries in 2020. Data were analyzed from January 1, 2019, to December 31, 2020.ExposureCOVID-19 pandemic.Main Outcomes and MeasuresThe primary outcome was the percentage change in the number of beneficiaries for each of the 10 most common ophthalmic procedures in each state.ResultsThere was an overall decrease of −17.9% in the rates of the 10 ophthalmic procedures from 2019 to 2020 (99% CI, −24.8% to −11.3%). The largest reduction was observed in laser peripheral iridotomy (−43.6%; 99% CI, −51.7% to −31.9%), while eye drug injections saw the smallest decrease (−1.5%; 99% CI, −3.3% to 0.3%). Cataract surgery also saw a reduction of −23.0% (99% CI, −28.8% to −18.7%). Regionally, the Northeast experienced the greatest reductions in cataract surgery (−27.9%; 99% CI, −32.8% to −22.3%).Conclusions and RelevanceThese results show that the COVID-19 pandemic caused a notable drop in the number of common ophthalmic procedures among Medicare beneficiaries, especially in laser peripheral iridotomy, while eye drug injections saw minimal changes. The Northeast experienced the largest reductions, highlighting the pandemic’s association with changes in eye care and indicating a need for focused recovery efforts in the hardest hit areas.
{"title":"COVID-19 Pandemic and Rates of Common Ophthalmic Procedures Among Medicare Beneficiaries","authors":"Raziyeh Mahmoudzadeh, Mariam Samuel, Sydney Wheeler, Mirataollah Salabati, Christopher T. Leffler, Jessica D. Randolph","doi":"10.1001/jamaophthalmol.2024.6065","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.6065","url":null,"abstract":"ImportanceThe COVID-19 pandemic has altered health care delivery, including ophthalmic care. Understanding how the pandemic has changed the rates of commonly performed ophthalmic procedures is crucial for assessing the broader implications for patient care and resource allocation.ObjectiveTo estimate the changes in the rates of the 10 most prevalent ophthalmic procedures among Medicare beneficiaries during the COVID-19 pandemic and to explore the geographic disparities in these shifts.DesignThis retrospective US cross-sectional study compared data from Medicare Part B National Summary Data Files for the calendar years 2019 and 2020. Participants included Medicare beneficiaries undergoing the 10 most common ophthalmic procedures. Data included a total of 3 879 533 procedure entries in 2019 and 3 181 439 entries in 2020. Data were analyzed from January 1, 2019, to December 31, 2020.ExposureCOVID-19 pandemic.Main Outcomes and MeasuresThe primary outcome was the percentage change in the number of beneficiaries for each of the 10 most common ophthalmic procedures in each state.ResultsThere was an overall decrease of −17.9% in the rates of the 10 ophthalmic procedures from 2019 to 2020 (99% CI, −24.8% to −11.3%). The largest reduction was observed in laser peripheral iridotomy (−43.6%; 99% CI, −51.7% to −31.9%), while eye drug injections saw the smallest decrease (−1.5%; 99% CI, −3.3% to 0.3%). Cataract surgery also saw a reduction of −23.0% (99% CI, −28.8% to −18.7%). Regionally, the Northeast experienced the greatest reductions in cataract surgery (−27.9%; 99% CI, −32.8% to −22.3%).Conclusions and RelevanceThese results show that the COVID-19 pandemic caused a notable drop in the number of common ophthalmic procedures among Medicare beneficiaries, especially in laser peripheral iridotomy, while eye drug injections saw minimal changes. The Northeast experienced the largest reductions, highlighting the pandemic’s association with changes in eye care and indicating a need for focused recovery efforts in the hardest hit areas.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"79 1 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1001/jamaophthalmol.2025.0060
{"title":"Error in Methods and eTable 1.","authors":"","doi":"10.1001/jamaophthalmol.2025.0060","DOIUrl":"10.1001/jamaophthalmol.2025.0060","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1001/jamaophthalmol.2024.6183
Sean T Berkowitz, Avni P Finn
{"title":"Can Medicare Data Describe COVID-19 Practice Pattern Changes?","authors":"Sean T Berkowitz, Avni P Finn","doi":"10.1001/jamaophthalmol.2024.6183","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.6183","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1001/jamaophthalmol.2024.6182
Carol L Shields
{"title":"Importance of Thickness When Evaluating Choroidal Tumors.","authors":"Carol L Shields","doi":"10.1001/jamaophthalmol.2024.6182","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.6182","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1001/jamaophthalmol.2024.6228
Zara Saleem, Alan D. Proia, Lars M. Wagner, Olivia J. Killeen, Sharon F. Freedman
This case report describes a rapidly growing conjunctival lesion in a 3-year-old patient, which was incompletely resected and diagnosed as rhabdomyosarcoma.
{"title":"Primary Conjunctival Rhabdomyosarcoma Presenting as an Enlarging Papillomatous Lesion in a 3-Year-Old","authors":"Zara Saleem, Alan D. Proia, Lars M. Wagner, Olivia J. Killeen, Sharon F. Freedman","doi":"10.1001/jamaophthalmol.2024.6228","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.6228","url":null,"abstract":"This case report describes a rapidly growing conjunctival lesion in a 3-year-old patient, which was incompletely resected and diagnosed as rhabdomyosarcoma.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"14 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1001/jamaophthalmol.2024.5304
Akshara R Legala, Marissa K Shoji, Don O Kikkawa
{"title":"Progressive Eyelid Lesions in a Woman With Essential Thrombocythemia.","authors":"Akshara R Legala, Marissa K Shoji, Don O Kikkawa","doi":"10.1001/jamaophthalmol.2024.5304","DOIUrl":"10.1001/jamaophthalmol.2024.5304","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"176-177"},"PeriodicalIF":7.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1001/jamaophthalmol.2024.5375
Patrick Yu-Wai-Man, Nancy J Newman, Valérie Biousse, Valerio Carelli, Mark L Moster, Catherine Vignal-Clermont, Thomas Klopstock, Alfredo A Sadun, Robert C Sergott, Rabih Hage, Simona Degli Esposti, Chiara La Morgia, Claudia Priglinger, Rustum Karanja, Magali Taiel, José-Alain Sahel
<p><strong>Importance: </strong>Limited studies have assessed the long-term benefit/risk of gene therapy for Leber hereditary optic neuropathy (LHON).</p><p><strong>Objective: </strong>To determine the safety and efficacy of lenadogene nolparvovec in patients with LHON due to the MT-ND4 gene variant for up to 5 years after administration.</p><p><strong>Design, setting, and participants: </strong>The RESCUE and REVERSE Long-Term Follow-up Study (RESTORE), conducted from 2018 to 2022, is the 5-year follow-up study of the 2 phase 3 clinical studies RESCUE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss Up to 6 Months From Onset in LHON Due to the MT-ND4 Mutation) and REVERSE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the MT-ND4 Mutation). At the end of each study, ie, 2 years after gene therapy administration, patients were offered enrollment in the RESTORE trial, a multinational, multicenter, prospective study, for an additional 3 years of follow-up. Patients with LHON due to the MT-ND4 gene variant received lenadogene nolparvovec in 1 eye and a sham injection in the other eye.</p><p><strong>Intervention: </strong>Lenadogene nolparvovec was administered as a single intravitreal injection in the RESCUE/REVERSE studies.</p><p><strong>Main outcomes and measures: </strong>Measures included best-corrected visual acuity (BCVA), quality of life using the National Eye Institute visual functioning questionnaire 25 (NEI VFQ-25), and adverse events.</p><p><strong>Results: </strong>Among the 76 patients who received gene therapy in the RESCUE (n = 39) and REVERSE (n = 37) studies, 72 (94.7%) completed these studies; 62 patients (81.6%) participated in the RESTORE trial, and 55 patients (72.4%) completed the 5-year follow-up. Participants were mostly male (49 [79.0%]) with a mean (SD) age of 35.9 (15.3) years at treatment. At baseline, the mean (SD) BCVA was 1.5 (0.5) logMAR (20/600 Snellen) in eyes to be treated with lenadogene nolparvovec and 1.4 (0.5) logMAR (20/500) in sham eyes. At the end of the RESCUE/REVERSE trials, ie, 2 years after treatment, eyes treated with lenadogene nolparvovec and eyes treated with sham reached a mean BCVA value of 1.4 (0.6) logMAR (20/500). The mean (SD) change from baseline to year 2 was -0.05 (0.6) logMAR (+1 line) and 0.01 (0.6) logMAR (-0 line) in gene therapy-treated and sham eyes, respectively (difference, -0.03; 95% CI, -0.16 to 0.09; P = .60). Five years after treatment, the bilateral improvement from nadir was similar to that observed at 2 years, with a mean (SD) change in BCVA of -0.4 (0.5) logMAR (more than +4 lines) for eyes treated with lenadogene nolparvovec and -0.4 (0.4) logMAR (+4 lines) for eyes treated with sham (difference, -0.05; 95% CI, -0.15 to 0.04; P = .27). An improvement of at least -0.3 logMAR (+3 lines) from the nadir in at least 1 eye was observed in 66.1% of participants (41 of 62). Between
{"title":"Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.","authors":"Patrick Yu-Wai-Man, Nancy J Newman, Valérie Biousse, Valerio Carelli, Mark L Moster, Catherine Vignal-Clermont, Thomas Klopstock, Alfredo A Sadun, Robert C Sergott, Rabih Hage, Simona Degli Esposti, Chiara La Morgia, Claudia Priglinger, Rustum Karanja, Magali Taiel, José-Alain Sahel","doi":"10.1001/jamaophthalmol.2024.5375","DOIUrl":"10.1001/jamaophthalmol.2024.5375","url":null,"abstract":"<p><strong>Importance: </strong>Limited studies have assessed the long-term benefit/risk of gene therapy for Leber hereditary optic neuropathy (LHON).</p><p><strong>Objective: </strong>To determine the safety and efficacy of lenadogene nolparvovec in patients with LHON due to the MT-ND4 gene variant for up to 5 years after administration.</p><p><strong>Design, setting, and participants: </strong>The RESCUE and REVERSE Long-Term Follow-up Study (RESTORE), conducted from 2018 to 2022, is the 5-year follow-up study of the 2 phase 3 clinical studies RESCUE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss Up to 6 Months From Onset in LHON Due to the MT-ND4 Mutation) and REVERSE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the MT-ND4 Mutation). At the end of each study, ie, 2 years after gene therapy administration, patients were offered enrollment in the RESTORE trial, a multinational, multicenter, prospective study, for an additional 3 years of follow-up. Patients with LHON due to the MT-ND4 gene variant received lenadogene nolparvovec in 1 eye and a sham injection in the other eye.</p><p><strong>Intervention: </strong>Lenadogene nolparvovec was administered as a single intravitreal injection in the RESCUE/REVERSE studies.</p><p><strong>Main outcomes and measures: </strong>Measures included best-corrected visual acuity (BCVA), quality of life using the National Eye Institute visual functioning questionnaire 25 (NEI VFQ-25), and adverse events.</p><p><strong>Results: </strong>Among the 76 patients who received gene therapy in the RESCUE (n = 39) and REVERSE (n = 37) studies, 72 (94.7%) completed these studies; 62 patients (81.6%) participated in the RESTORE trial, and 55 patients (72.4%) completed the 5-year follow-up. Participants were mostly male (49 [79.0%]) with a mean (SD) age of 35.9 (15.3) years at treatment. At baseline, the mean (SD) BCVA was 1.5 (0.5) logMAR (20/600 Snellen) in eyes to be treated with lenadogene nolparvovec and 1.4 (0.5) logMAR (20/500) in sham eyes. At the end of the RESCUE/REVERSE trials, ie, 2 years after treatment, eyes treated with lenadogene nolparvovec and eyes treated with sham reached a mean BCVA value of 1.4 (0.6) logMAR (20/500). The mean (SD) change from baseline to year 2 was -0.05 (0.6) logMAR (+1 line) and 0.01 (0.6) logMAR (-0 line) in gene therapy-treated and sham eyes, respectively (difference, -0.03; 95% CI, -0.16 to 0.09; P = .60). Five years after treatment, the bilateral improvement from nadir was similar to that observed at 2 years, with a mean (SD) change in BCVA of -0.4 (0.5) logMAR (more than +4 lines) for eyes treated with lenadogene nolparvovec and -0.4 (0.4) logMAR (+4 lines) for eyes treated with sham (difference, -0.05; 95% CI, -0.15 to 0.04; P = .27). An improvement of at least -0.3 logMAR (+3 lines) from the nadir in at least 1 eye was observed in 66.1% of participants (41 of 62). Between","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"99-108"},"PeriodicalIF":7.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1001/jamaophthalmol.2024.5274
Shilan Seyed Ahmadi, Johnny Ludvigsson, Henrik Imberg, Thomas Nyström, Marcus Lind
{"title":"Risk Factors for Retinopathy in Young Adults With Type 1 Diabetes.","authors":"Shilan Seyed Ahmadi, Johnny Ludvigsson, Henrik Imberg, Thomas Nyström, Marcus Lind","doi":"10.1001/jamaophthalmol.2024.5274","DOIUrl":"10.1001/jamaophthalmol.2024.5274","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"184-186"},"PeriodicalIF":7.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：